F-1/A: Nasus Pharma Files for IPO Amidst Significant Losses and Going Concern Doubts

Nasus Pharma Ltd., a clinical-stage pharmaceutical company, has filed an F-1/A registration statement for an initial public offering of 1.25 million ordinary shares, seeking to raise approximately $9.5 million to fund its intranasal drug development programs, despite reporting substantial accumulated deficits and raising 'substantial doubt' about its ability to continue as a going concern.

Summary

• Nasus Pharma Ltd. is a clinical-stage specialty pharmaceutical company focused on developing intranasal drugs for emergency medical conditions, utilizing its proprietary Powder-Based Intranasal (PBI) technology.
• The company is pursuing an Initial Public Offering (IPO) of 1,250,000 ordinary shares at an assumed price of $9.00 per share, aiming to raise approximately $9.5 million in net proceeds.
• Primary product focus is NS002 (Intranasal Epinephrine) for severe allergies and anaphylaxis, which has completed a Phase 2 study, with plans for two additional Phase 2 studies and a pivotal Phase 3 study.
• Development of NS001 (Intranasal Naloxone) for opioid overdose has been paused, with the company seeking partnering opportunities for its further development, despite having completed a pivotal Phase 3 study.
• The company reported a net loss of $1.532 million for the year ended December 31, 2024, an increase from $1.051 million in 2023.
• Accumulated deficit as of December 31, 2024, stood at $12.7 million, with cash and cash equivalents of $0.284 million.
• Management has concluded that 'substantial doubt' exists about the company's ability to continue as a going concern, as current cash is expected to fund operations only through September 2025.
• The company intends to use $6 million to $7 million of the IPO proceeds for the Intranasal Epinephrine program, including manufacturing scale-up and additional Phase 2 studies, with the remainder for general and administrative purposes.
• Nasus Pharma holds several granted patents for its dry powder formulations, including one specifically for Naloxone, and has numerous pending applications worldwide.
• The company relies on Aptar Group Inc. as a sole supplier for its intranasal Unit Dose Spray (UDS) delivery system, and has an outstanding payment of $529,000 to Aptar, which previously issued a notice of default.
• The Phase 2 study for NS002, while showing promising PK results (faster absorption, quicker peak plasma levels compared to IM Epinephrine), was not powered for statistical significance, meaning observed effects may not be accurate due to small sample size.
• The company is an 'emerging growth company' and a 'foreign private issuer,' allowing it to take advantage of certain exemptions from U.S. public company reporting and corporate governance requirements.

Sentiment

Score: 2

Explanation: The company is in a very early clinical stage with no approved products and has incurred significant and increasing operating losses. The explicit 'substantial doubt about its ability to continue as a going concern' due to limited cash runway (through September 2025) indicates severe financial distress and high risk, despite promising early clinical data for its lead candidates. The reliance on the IPO and future capital raises for survival, coupled with the early stage of development and competitive landscape, points to a highly speculative and precarious investment.

Positives

• Proprietary Powder-Based Intranasal (PBI) technology shows promise for rapid and higher drug absorption compared to liquid-based solutions, with initial clinical trials demonstrating quicker and higher absorption.
• NS002 (Intranasal Epinephrine) Phase 2 study showed immediate absorption and quicker achievement of higher peak plasma Epinephrine levels compared to intramuscular (IM) Epinephrine injections, reaching statistical significance after four minutes.
• NS002 demonstrated superior enantiomeric stability, with 100% of Epinephrine remaining in the active form, unlike commercial EpiPen devices which showed significant levels of inactive enantiomers, even before expiration.
• NS001 (Intranasal Naloxone) pivotal Phase 3 study consistently showed a significant advantage in the first 30 minutes after administration, creating higher plasma levels of Naloxone in the critical immediate period.
• The company has successfully scaled up its manufacturing process for commercial quantities of its powder products and collaborated with an FDA-approved vendor for filling and packaging.
• A strong intellectual property portfolio exists with several granted U.S. patents and numerous pending applications globally for its dry powder formulations and Epinephrine-specific treatments.
• The company's leadership team possesses extensive experience in the biotechnology industry, drug development, and managing publicly traded companies.

Negatives

• The company has incurred significant operating losses since inception, with an accumulated deficit of $12.7 million as of December 31, 2024.
• No revenues have been generated from existing products, and the company anticipates continued significant losses for the foreseeable future.
• Current cash and cash equivalents of $0.284 million are only expected to fund operations through September 2025, raising 'substantial doubt' about the company's ability to continue as a going concern.
• The Phase 2 portion of the NS002 study was not powered for statistical significance, indicating a high chance that observed effects may not be accurate due to small sample size.
• Development of NS001 (Intranasal Naloxone) has been paused, and the company plans to pursue partnering opportunities, indicating a potential delay or uncertainty in its commercialization.
• The company is dependent on a sole supplier (Aptar) for its UDS delivery system and has an outstanding payment of $529,000 to Aptar, which previously issued a notice of default.
• The company has identified material weaknesses in its internal control over financial reporting as of December 31, 2023, and has not yet remediated them, posing risks to accurate financial reporting and investor confidence.
• The company has limited manufacturing experience and currently has no manufacturing facilities, relying on third-party manufacturers for commercial scale production, which introduces supply chain risks.

Risks

• Inability to obtain additional financing on acceptable terms or at all, which could lead to delays, reduction in scope, or elimination of research, development, or commercialization plans.
• Uncertainty regarding regulatory approval for any product candidates, which is a lengthy, expensive, and uncertain process, potentially leading to delays or denial of commercialization.
• Clinical trials may be prolonged, delayed, or unsuccessful, potentially due to difficulties in patient enrollment, regulatory approvals, or unforeseen safety issues.
• Product candidates may lack sufficient efficacy or cause undesirable side effects not previously identified, leading to delayed or prevented regulatory approval or commercialization.
• Reliance on third-party manufacturers and suppliers for raw materials and components (e.g., Epinephrine, Aptar UDS) poses risks of delays, price increases, or unavailability.
• Intellectual property protection may be limited, as patent applications may not result in issued patents, or issued patents may not be broad enough to prevent competition or may be challenged.
• Intense competition in the pharmaceutical industry from companies with greater resources, brand recognition, and experience could limit market acceptance and sales of Nasus Pharma's products.
• Exposure to fluctuations in currency exchange rates (NIS, Euro vs. USD) could adversely affect financial results.
• Potential political, economic, and military instability in Israel, where operations are located, could adversely affect business operations and financial results.
• Risk of product liability lawsuits due to the inherent nature of pharmaceutical products, which could incur substantial liabilities and limit commercialization.
• Failure to comply with post-marketing regulatory requirements could lead to enforcement actions, penalties, or product recalls.
• Changes in regulatory requirements or guidance could increase costs, delay development timelines, or reduce the likelihood of successful clinical trial completion.
• The company's management team has limited experience managing a U.S. public company, which could lead to difficulties in compliance and oversight.
• Security breaches, including cybersecurity incidents, could disrupt operations, lead to data loss, and incur significant costs or liabilities.
• The company's status as an emerging growth company and foreign private issuer allows for exemptions from certain reporting and governance requirements, which may result in less information and protection for investors.

Future Outlook

The company expects to continue incurring substantial operating losses for the foreseeable future as it progresses its clinical development programs, particularly for Intranasal Epinephrine. It anticipates needing significant additional funding beyond the IPO proceeds to complete research and development, attain regulatory approvals, and commercialize its products. The company plans to focus development and regulatory efforts on Intranasal Epinephrine and other preclinical programs, while seeking partnering opportunities for NS001. Future plans include additional Phase 2 studies, a pivotal Phase 3 study, and pediatric studies for NS002, with an NDA submission targeted for Q2 2027. The company also aims to explore regulatory approval in the EU and develop additional pipeline programs using its PBI technology.

Management Comments

• "Our mission is to offer better protection to patients during acute, severe and life-threatening medical conditions by an effective, user-friendly and immediately active PBI specialized products."
• "We believe that PBI may be superior over liquid-based solutions due to potentially significantly higher dispersion of powder throughout the nasal cavity, thus creating a larger absorption area and enabling more rapid and higher drug absorption."
• "The initial clinical trials of our PBI products involving different molecules performed thus far have demonstrated quicker and higher drug absorption over similar solution-based nasal products."
• "We currently intend to focus our development and regulatory approval efforts on our Intranasal Epinephrine and other preclinical programs and plan to pursue partnering opportunities for further development of NS001."
• "We believe that our cost structure enables us to compete in the market and maintain extremely high margins."
• "Our powder Epinephrine nasal spray is stable and devoid of the stability issues of liquid-based Epinephrine products in the market."
• "Our leadership and executives are highly experienced biotech executives that have accumulated precious experience with regards to our technology as well as relevant industry experience."
• "We believe that our powder intranasal technology showed consistent advantage, including quicker and higher absorption, over the current market leader in intranasal Naloxone. This advantage is highly meaningful clinically since it creates higher plasma levels of the antidote in the most critical first few minutes of overdose rescue."

Industry Context

The company operates in the intensely competitive pharmaceutical industry, specifically targeting the intranasal drug delivery market, which was estimated at $59 billion in 2022 and is projected to grow to $93.7 billion by 2029. This market is driven by the advantages of non-invasive, rapid drug delivery for acute conditions. The company's primary focus, Intranasal Epinephrine, competes in a global Epinephrine market valued at $2.3 billion in 2024, projected to reach $4.4 billion by 2032, dominated by auto-injectors like EpiPen. Key competitors in the intranasal Epinephrine space include ARS Pharmaceuticals (Neffy), Bryn Pharma, Orexo AB, and Aquestive Therapeutics, all developing alternative administration routes. For Intranasal Naloxone, the market is transitioning from injectables, with current leaders like Narcan (Emergent BioSolutions) and Kloxxado (Hikma Pharmaceuticals). The company aims to differentiate through its powder-based technology's potentially superior absorption profile and stability compared to liquid formulations.

Comparison to Industry Standards

• NS002 (Intranasal Epinephrine) pilot study showed a median time to plasma concentration of 100pg/ml (clinical effect threshold) three times shorter for 3.2 mg dosage under allergenic challenge compared to IM EpiPen, indicating a potential clinical advantage in the short therapeutic window.
• NS002 Phase 2 study showed statistically significant higher Epinephrine plasma concentration after four minutes compared to IM Epinephrine injection, with a T100pg (time to clinical threshold) of 3.6 minutes for NS002 4mg versus 9 minutes for EpiPen.
• 91% of patients receiving NS002 4mg achieved the clinical threshold level of 100 pg/ml compared to 55% for EpiPen, suggesting better consistency in reaching therapeutic levels.
• NS002 demonstrated 100% enantiomeric purity, meaning no detectable levels of inactive enantiomers, contrasting with commercial EpiPen devices which showed high levels of inactive enantiomers (up to 5.71% in adult dose and 5.70% in pediatric dose, with some exceeding FDA limits of 1.5% even before expiration), indicating superior stability.
• NS001 (Intranasal Naloxone) pilot study showed a partial AUC0-4 minutes approximately 7-fold higher, partial AUC0-10 minutes approximately 4-fold higher, and partial AUC10-30 minutes approximately 1.6-fold higher compared to Narcan, suggesting significantly faster absorption in the critical immediate period.
• NS001 pivotal study consistently showed a significant advantage in the first 30 minutes after administration compared to Narcan, supporting the faster absorption profile observed in the pilot study.
• The company's powder technology is stated to cover a significantly larger surface area of the nasal cavity compared to liquid nasal sprays, leading to more rapid and larger drug absorption, a phenomenon supported by third-party studies (Djupesland, Williams et al.) and observed in the company's own clinical studies when compared head-to-head with similar liquid nasal products.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any legal proceedings that, in management's opinion, are likely to have a material adverse effect on its business.
• A supplier associated with the discontinued Taffix business commenced legal proceedings in May 2022 for $92,000 in professional fees; the company recorded this as a liability.
• Aptar Group Inc. sent a notice of default on October 5, 2022, claiming alleged breach of contractual obligations and outstanding payments of $529,000, plus termination fees of $450,000 for NS001. The company contested the allegations and believes it is not probable it will be required to pay the termination fees. No legal proceeding has been initiated by Aptar since February 2023.

Related Party Transactions

• Services agreements with executive officers (Dan Teleman, Udi Gilboa, Dr. Dalia Megiddo, Dr. Tair Lapidot, Oren Elmaliach) include salaries, bonuses, equity compensation, and expense reimbursements, with some voluntary salary reductions in 2022.
• Loans received from Dr. Ronnie Hershman (director/shareholder) and Michael Gibber (shareholder) in July 2022 ($500,000) and from Dr. Ronnie Hershman, Dr. Dalia Megiddo, and Mr. Udi Gilboa in February 2023 ($60,000) were converted into 2024 SAFEs in August 2024.
• SAFEs (Simple Agreements for Future Equity) were issued in 2022 ($966,000), 2023 ($995,000), and 2024 ($1,986,500, with $300,000 canceled), with participation from co-founders, directors, and shareholders. These SAFEs convert into Ordinary Shares upon IPO or other liquidity events, typically at a discount.
• License agreement with Formulex Pharma Innovations Ltd. (owned by co-founders and a director) grants exclusive rights to its patent for dry powder compositions, with royalties of 0.5% of net sales capped at $100,000.
• Services agreement with Formulex for chemical manufacturing and controls services at a fixed monthly cost of $5,000, with additional one-time development services provided.
• Subcontractor agreement with Formulex (effective December 5, 2024) for potential participation in tenders, with a maximum aggregate consideration of $800,000.
• Secretarial services provided by Topnotch Consultancy (2009) Ltd. (owned by Mr. Udi Gilboa) for a monthly fee of NIS 15,000 ($4,119) as of April 2024.
• Office space leased from Topnotch for a monthly fee of NIS 12,000 ($3,295).

Stakeholder Impact

• **Shareholders:** Significant dilution for new investors (88% dilution in net tangible book value) due to the IPO pricing relative to historical book value. Existing shareholders, particularly principal shareholders and management, will retain significant influence (72% beneficial ownership post-IPO). The 'going concern' warning poses a substantial risk of loss of entire investment.
• **Employees:** The company plans to significantly increase its organization size, including hiring managerial, operational, and financial personnel, which could create new employment opportunities. However, the company's financial instability and 'going concern' risk could impact job security.
• **Customers/Patients:** Potential for new, user-friendly, and effective intranasal drug delivery options for emergency medical conditions like anaphylaxis and opioid overdose, offering advantages over current injectable or liquid-based treatments. However, product availability is contingent on regulatory approvals and successful commercialization.
• **Suppliers/Creditors:** The company's reliance on sole suppliers (e.g., Aptar) and outstanding liabilities (e.g., $529,000 to Aptar) indicate potential risks for suppliers if financial stability is not achieved. Creditors face 'substantial doubt' about the company's ability to meet its obligations.
• **Regulatory Bodies:** The company's operations and product development are subject to extensive regulation by the FDA, EMA, and other authorities. Compliance failures or adverse findings could lead to sanctions, fines, or delays in product approvals, impacting public health and safety.

Next Steps

• Complete manufacturing scale-up and technology transfer for NS002 (Intranasal Epinephrine) by Q3 2025.
• Initiate two additional Phase 2 studies for NS002 in Q4 2025 to determine optimal administration methods and carry-over effects.
• Submit an Investigational New Drug (IND) application for NS002 in Q3 2026.
• Initiate a pivotal Phase 3 study for NS002, including a self-administration subsection, in Q3 2026.
• Initiate a pediatric study for NS002 in Q4 2026, with details to be agreed upon with the FDA.
• Perform stability testing, reliability studies, and usability studies for NS002.
• Submit a New Drug Application (NDA) dossier for marketing approval of NS002 by Q2 2027.
• Pursue partnering opportunities for the further development of NS001 (Intranasal Naloxone).
• Explore regulatory approval of products outside the United States, including seeking scientific advice from European countries.
• Utilize platform technology to develop additional preclinical pipeline programs for other indications (Intranasal Midazolam, Intranasal Atropine, Intranasal Ondansetron).
• Remediate identified material weaknesses in internal control over financial reporting.
• Appoint an internal auditor within 90 days following the IPO consummation.

Key Dates

Recommendation

The company is a clinical-stage pharmaceutical firm with no revenue-generating products and a significant accumulated deficit of $12.7 million. Critically, management has identified 'substantial doubt' about its ability to continue as a going concern, with current cash expected to last only until September 2025. While the IPO aims to raise $9.5 million, this amount is explicitly stated as insufficient to complete all necessary R&D for commercialization. The primary product, NS002, is still in early Phase 2, and the pivotal Phase 3 study is yet to begin, with NDA submission not expected until Q2 2027. The Phase 2 data, while promising, was not statistically significant. The high financial risk, early stage of product development, and explicit going concern warning make this a highly speculative investment with a significant risk of capital loss. A seasoned investor would likely avoid or exit such a position due to the severe financial instability and long, uncertain path to profitability.

Keywords

Intranasal Epinephrine, Anaphylaxis, Intranasal Naloxone, Opioid Overdose, Powder-Based Intranasal Technology, PBI, Clinical Stage, Pharmaceutical, Biotechnology, IPO, SEC Filing, F-1/A, NS002, NS001, Drug Delivery, Emergency Medicine, FDA Approval, Clinical Trials, Going Concern, Israel